Title: Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease.

Authors: Vaucher J, Marques-Vidal P, Preisig M, Waeber G, Vollenweider P

Journal: European heart journal

Year: 2014 Apr

Volume: 35

Issue: 15

Pages: 958-9

DOI: 10.1093/eurheartj/ehu064
Population and economic impact of the 2013 ACC/AHA guidelines compared to European guidelines to prevent cardiovascular disease

Running title: population impact of US and European CVD guidelines

Julien Vaucher, MD1; Pedro Marques-Vidal, MD, PhD, FESC2; Martin Preisig, MD3;
Gérard Waeber, MD1* and Peter Vollenweider, MD1*

1 Department of Medicine, Internal Medicine; 2 Institute of Social and Preventive Medicine (IUMSP); 3 Department of Psychiatry; all at CHUV and Faculty of biology and medicine, Lausanne, Switzerland

*GW and PV contributed equally to this manuscript and are therefore both to be considered as last authors.

Authors’ emails:

Julien Vaucher: Julien.Vaucher@chuv.ch
Pedro Marques-Vidal: Pedro-Manuel.Marques-Vidal@chuv.ch
Martin Preisig: Martin.Preisig@chuv.ch
Gérard Waeber: Gerard.Waeber@chuv.ch
Peter Vollenweider: Peter.Vollenweider@chuv.ch

Corresponding author:

Julien Vaucher, MD
Etude CoLaus
Bâtiment des Instituts
19, rue du Bugnon
1005 Lausanne
Switzerland
Phone: +41 21 314 03 46
Fax: +41 21 314 80 37
Email: julien.vaucher@chuv.ch

Word count

Abstract: 246
Main text: 468
with references and tables: 1,152

Number of tables: 1
Figures: 0
References: 7

Keywords: CVD risk; population study; guidelines; primary prevention
Recently, the American College of Cardiology (ACC) and the American Heart Association (AHA) issued new guidelines on management of cardiovascular (CV) risk in primary prevention. They developed a new CV risk calculator (new pooled cohort atherosclerotic CV disease risk equation) targeting individuals between 40-75 years and based on 4 American population-based cohorts. Statin treatment is recommended for individuals with an estimated 10-year risk of CV disease (CVD) ≥7.5%, including stroke. Conversely, the guidelines of the European Society of Cardiology (ESC) advocate the use of the SCORE equation for individuals aged between 40 and 65 years, and initiation of a statin treatment is recommended if the estimated 10-year risk of death from CVD is ≥5%. Whether applying the ACC/AHA guidelines has similar public health consequences as applying the ESC guidelines is currently unknown. Hence, we used the data from a large, population-based study, to assess the countrywide population and economic impact of these new guidelines, supposing full adherence to treatment recommendations.

Data from the Swiss CoLaus study, collected between 2003 and 2006 in 3,297 participants (1,854 women) aged 50 to 75 years, was used. Ten-year CVD risk was computed according to the Swiss SCORE (ESC) and the 2013 ACC/AHA risk equations; results were extrapolated to the Swiss population of the same age group. The Swiss SCORE equation has been validated in individuals up to 75 years of age. Daily cost of treatment was estimated using one widely used statin, i.e. atorvastatin.

The results are summarized in the table. Irrespective of the risk equation used, the prevalence of high-risk individuals increased considerably with age, exceeding 80% among participants aged over 70 years. Extrapolated to the Swiss population, applying the ACC/AHA guidelines more than doubled the prevalence of high-risk individuals (2.2-fold in men and 1.9 fold in women) relative to the SCORE function. The biggest differences were observed for age group 50 to 60 years, where the ACC/AHA guidelines led to a 30-fold increase in the number of high-risk individuals relative to the ESC guidelines. Full compliance with the ACC/AHA guidelines would also lead to an extra cost of treatment of 1.124 million CHF per day (410 million CHF, or 333.7 million €, per year).

We conclude that, relative to the ESC guidelines, the 2013 ACC/AHA guidelines lead to a considerable increase in the number of high-risk individuals susceptible of receiving statin treatment. This increase is particularly strong in the age group 50-60 years. One likely explanation for this discrepancy may be due to differences in the prevalence of CV risk factors between the US and Europe. Consequently, if fully implemented, the ACC/AHA guidelines might lead to a considerable increase in primary prevention costs of CVD. Further studies are needed to validate the new ACC/AHA risk equation and to assess the cost-effectiveness of the ACC/AHA guidelines in non-US countries.
Authors’ contributions

JV collected data and wrote most of the article. PMV made the statistical analyses and wrote part of the article; MP revised the article for important intellectual content; GW and PV were the initiators of this study and revised the article for important intellectual content. PMV had full access to the data and is the guarantor of the study.

Funding

The CoLaus study was supported by grants from the Swiss National Science Foundation [grant no: FN 33CSCO-122661 and 33CSCO-139468]; GlaxoSmithKline; the Faculty of Biology and Medicine of Lausanne, Switzerland; and the Swiss Society of Internal Medicine.

Competing interests

GW and PV received an unrestricted grant from GSK to build the CoLaus study. The other authors report no other conflict of interest.
References


Table: simulations of the population impact and of daily costs related to treatment with atorvastatin in Switzerland according to the European Society of Cardiology (ESC) or 2013 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines

<table>
<thead>
<tr>
<th>Swiss population</th>
<th>Population at risk *</th>
<th>Ratio ACC/AHA to ESC †</th>
<th>Daily cost of treatment ‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ESC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
<td>Total</td>
</tr>
<tr>
<td>[50-60]</td>
<td>561'013</td>
<td>551'105</td>
<td>1'112'118</td>
</tr>
<tr>
<td>[60-70]</td>
<td>429'528</td>
<td>448'861</td>
<td>878'389</td>
</tr>
<tr>
<td>[70-75]</td>
<td>176'448</td>
<td>205'307</td>
<td>381'755</td>
</tr>
<tr>
<td>All</td>
<td>1'814'130</td>
<td>1'841'332</td>
<td>3'655'462</td>
</tr>
<tr>
<td></td>
<td>ACC/AHA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
<td>Total</td>
</tr>
<tr>
<td>[50-60]</td>
<td>561'013</td>
<td>551'105</td>
<td>1'112'118</td>
</tr>
<tr>
<td>[60-70]</td>
<td>429'528</td>
<td>448'861</td>
<td>878'389</td>
</tr>
<tr>
<td>[70-75]</td>
<td>176'448</td>
<td>205'307</td>
<td>381'755</td>
</tr>
<tr>
<td>All</td>
<td>1'166'989</td>
<td>1'205'273</td>
<td>2'372'262</td>
</tr>
</tbody>
</table>

* according to the ACC/AHA (new pooled cohort atherosclerotic CV disease risk equation) or ESC guidelines (Swiss SCORE equation).
† ratio of the number of subjects at risk according to ACC/AHA guidelines to the number of subjects at risk according to ESC guidelines. NA: not assessable.
‡ expressed in 1,000 CHF. To obtain €, multiply by 0.814; to obtain US$, multiply by 1.110. Currency exchange rates as of January 3rd 2014 were applied.
§ fixed daily price independent of dosing (10-80 mg).
|| SCORE equation do not predict CV risk for women under 60 years.